EP2748328A4 - PEG-INTERFERON LAMBDA 1 CONJUGATES - Google Patents

PEG-INTERFERON LAMBDA 1 CONJUGATES

Info

Publication number
EP2748328A4
EP2748328A4 EP12825651.8A EP12825651A EP2748328A4 EP 2748328 A4 EP2748328 A4 EP 2748328A4 EP 12825651 A EP12825651 A EP 12825651A EP 2748328 A4 EP2748328 A4 EP 2748328A4
Authority
EP
European Patent Office
Prior art keywords
conjugates
peg
interferon lambda
interferon
lambda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12825651.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2748328A1 (en
Inventor
Nhan Ho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanogen Pharmaceutical Biotechnology
Original Assignee
Nanogen Pharmaceutical Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanogen Pharmaceutical Biotechnology filed Critical Nanogen Pharmaceutical Biotechnology
Publication of EP2748328A1 publication Critical patent/EP2748328A1/en
Publication of EP2748328A4 publication Critical patent/EP2748328A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP12825651.8A 2011-08-25 2012-03-01 PEG-INTERFERON LAMBDA 1 CONJUGATES Withdrawn EP2748328A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
VN201102222 2011-08-25
PCT/US2012/027317 WO2013028233A1 (en) 2011-08-25 2012-03-01 Peg-interferon lambda 1 conjugates

Publications (2)

Publication Number Publication Date
EP2748328A1 EP2748328A1 (en) 2014-07-02
EP2748328A4 true EP2748328A4 (en) 2015-03-04

Family

ID=47746747

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12825651.8A Withdrawn EP2748328A4 (en) 2011-08-25 2012-03-01 PEG-INTERFERON LAMBDA 1 CONJUGATES

Country Status (9)

Country Link
EP (1) EP2748328A4 (enrdf_load_stackoverflow)
JP (1) JP2014525939A (enrdf_load_stackoverflow)
CN (1) CN103228792A (enrdf_load_stackoverflow)
AU (1) AU2012299423A1 (enrdf_load_stackoverflow)
BR (1) BR112014004302A2 (enrdf_load_stackoverflow)
CA (1) CA2846092A1 (enrdf_load_stackoverflow)
RU (1) RU2014111179A (enrdf_load_stackoverflow)
WO (1) WO2013028233A1 (enrdf_load_stackoverflow)
ZA (1) ZA201401159B (enrdf_load_stackoverflow)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3416675T3 (pl) * 2016-02-19 2021-10-11 Eiger Biopharmaceuticals, Inc. Leczenie zakażenia wirusem zapalenia wątroby typu delta za pomocą interferonu lambda
ES3015227T3 (en) 2017-03-16 2025-04-30 Evangelos Andreakos Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder
RU2678332C1 (ru) * 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
CN112245570A (zh) 2019-07-22 2021-01-22 厦门特宝生物工程股份有限公司 一种基于干扰素的疾病治疗方法
KR20230157947A (ko) 2021-01-21 2023-11-17 샤먼 아모이탑 바이오테크 컴퍼니 리미티드 암 재발 방지를 위한 방법 및 약제학적 조합
KR20230157313A (ko) 2021-01-21 2023-11-16 샤먼 아모이탑 바이오테크 컴퍼니 리미티드 인터페론-기반 암 치료 방법 및 약제학적 조합
WO2024121424A1 (en) 2022-12-09 2024-06-13 Daniel Zagury Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CN1176137C (zh) * 2002-01-15 2004-11-17 泛亚生物技术有限公司 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用
CN1927388B (zh) * 2004-09-10 2011-02-02 北京金迪克生物技术研究所 含有人干扰素的药物组合物
WO2006133089A2 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
DK1931704T3 (da) * 2005-10-04 2011-03-14 Zymogenetics L L C Frembringelse og rensning af IL-29
CN101002942B (zh) * 2007-01-08 2010-07-21 湖南大学 一种peg化脂质体纳米颗粒
EP2296691A1 (en) * 2008-06-05 2011-03-23 ZymoGenetics, L.L.C. Use of pegylated type iii interferons for the treatment of hepatitis c

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AHAD ET AL: "Interferon to PEG-Interferon: A Review", THE JOURNAL OFTEACHERS ASSOCIATIONRMC, RAJSHAHI, vol. 17, no. 2, 1 December 2004 (2004-12-01), XP002734715 *
MUIR ANDREW J ET AL: "Phase 1b Study of Pegylated Interferon Lambda 1 With or Without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection", HEPATOLOGY, vol. 52, no. 3, September 2010 (2010-09-01), pages 822 - 832, XP002734714, ISSN: 0270-9139 *
See also references of WO2013028233A1 *

Also Published As

Publication number Publication date
RU2014111179A (ru) 2015-09-27
CN103228792A (zh) 2013-07-31
BR112014004302A2 (pt) 2017-06-20
JP2014525939A (ja) 2014-10-02
EP2748328A1 (en) 2014-07-02
AU2012299423A1 (en) 2014-03-06
CA2846092A1 (en) 2013-02-28
ZA201401159B (en) 2015-04-29
WO2013028233A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
ZA201401159B (en) Peg-interferon lambda 1 conjugates
FR2971446B3 (fr) Coiff'rasoir
GB201121094D0 (en) Concept 58
GB201120424D0 (en) Concept 66
GB201119762D0 (en) Concept 65
GB201117189D0 (en) Concept 64
GB201114517D0 (en) Concept 15
GB201114547D0 (en) Concept 23
GB201114486D0 (en) Concept 6
GB201114487D0 (en) Concept 16
GB201114489D0 (en) Concept 12 12
GB201114502D0 (en) Concept 53
GB201114503D0 (en) Concept 54
GB201114511D0 (en) Concept 7
GB201114544D0 (en) Concept 25
GB201114519D0 (en) Concept 31
GB201114522D0 (en) Concept 32
GB201114523D0 (en) Concept 33
GB201114525D0 (en) Concept 3
GB201114529D0 (en) Concept 34
GB201114530D0 (en) Concept 35
GB201114532D0 (en) Concept 36
GB201114534D0 (en) Concept 37
GB201114535D0 (en) Concept 38
GB201114546D0 (en) Concept 22

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140311

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20150203

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 11/00 20060101AFI20150123BHEP

Ipc: C12P 21/04 20060101ALI20150123BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151203